Company
Headquarters: Nanyang, China
Employees: 1,243
CEO: Mr. Zhiming Cao
HK$791.3 Million
HKD as of July 1, 2024
US$101.3 Million
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
Fusen Pharmaceutical Company Limited, an investment holding company, manufactures and sells pharmaceutical products under the Fusen brand in the People's Republic of China. It offers over the counter and prescription based proprietary Chinese medicine (PCM) products in various dosage forms. The company's product portfolio includes Shuanghuanglian-based cold medicines comprising Shuanghuanglian oral solutions and Shuanghuanglian injections; and other PCM and western medicine products, such as Chaihu injection, as well as flunarizine hydrochloride capsules, compound ferrous sulfate granules, and clarithromycin sustained release tablets. In addition, it researches, develops, produces, and sells various PCMs and chemical medicines for the treatments of cold and fever, cardiovascular and gynecological diseases, and anemia. Further, the company offers business management and consulting services. The company was founded in 2003 and is headquartered in Nanyang, China.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Fusen Pharmaceutical Company Ltd has the following listings and related stock indices.
Stock: HKEX: 1652 wb_incandescent